WINSTON-SALEM, N.C., June 11, 2024 ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an.
ProKidney (NASDAQ:PROK – Free Report) had its price objective boosted by Bank of America from $3.00 to $4.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Bank of America currently has a neutral rating on the stock. Separately, Morgan Stanley began coverage on ProKidney in a report on Thursday, March 7th. […]
ProKidney (NASDAQ:PROK) Trading Down 6 2% themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
ProKidney Corp. (NASDAQ:PROK – Get Free Report) shares were up 4.7% during trading on Tuesday . The stock traded as high as $3.62 and last traded at $3.53. Approximately 29,186 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 688,385 shares. The stock had previously closed at $3.37. […]
ProKidney Corp (NASDAQ:PROK) Insider Control Empresarial De Capital Buys 14,000 Shares dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.